The Pharmagellan Guide to Biotech Forecasting and Valuation
| Author | : | |
| Rating | : | 4.68 (507 Votes) |
| Asin | : | 099840750X |
| Format Type | : | paperback |
| Number of Pages | : | 138 Pages |
| Publish Date | : | 2014-04-21 |
| Language | : | English |
DESCRIPTION:
I highly recommend it, both to people who build the models and people like me who have to look at them." — Briggs Morrison, CEO, Syndax Pharmaceuticals . Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side. If you’re trying to develop a reasonable view of the value of your program or your company—and a view that will appear reasonable to the folks across the table—this beautiful book breaks it down for you." — Michael Gilman, serial biotech CEO (Stromedix, Padlock Therapeutics) "Does an excellent job of defining the inputs that go into modeling, explains how they can be forecasted, and shows how it all ties together. Vetted benchmarks for key drivers of income, expenses, and valuation. Over 150 current references from peer-reviewed research, industry white papers, and SEC filings. Proprietary analyses by Pharmagellan's experienced consulting team. This book is for you."Deserves a spot on the bookshelf of every biotech CFO." — Bruce Booth, Partner, Atlas Venture "A helpful and insightful resource for anyone who finds themselves staring at a blank Excel spreadsheet." — Adam Feuerstein, Senior Columnist, TheStreet "This is the book I wish I'd had when I started out." — Vin Milano, CEO, Idera Pharmaceuticals "Invaluable, rigorously detailed, and well validated." — Joh
Frank S. Seth Robey, PhD, and Andrew Matthews, MD, are former and current associate consultants, respectively, at Pharmagellan. . He also maintains an active presence on Twitter (@Frank_S_David). David, MD, PhD, is the founder and managing director of the biotech consultancy Pharmagellan (pharmagellan), an academic researcher and author on life sciences R&D, commercialization, and strategy, and a blogger about biomedical innovation at Forbes
"Probably the most useful biotech forecasting tool aside from my HP12c" according to Smartypants. Finally. A practical guide to valuation in biotech. If you're looking to figure out whether you should use IRR or NPV or how to build that NPV spreadsheet, this is not the book for you. You don't have to be an expert number cruncher but the book assumes a basic financial knowledge and understanding of general valuation concepts. This is why the book is so useful. Models are only as good as what goes into them. David, who clearly has deep industry experience, does a fan. Thoroughly researched and well organized Doug Martin Read book cover to cover the day I received it. The book is organized very well and provides an excellent structure and guide for those new to the field as well as interesting benchmarks and data for the more experienced and seasoned.I highly recommend for buy and sell-side analysts seeking to refine their own valuations or understand others, consultants who conduct pipeline commercial assessments or conduct diligence/ support licensing & partnerships, and those in in-. Five Stars ams Short, concise, and rich in relevant information
David, MD, PhD, is the founder and managing director of the biotech consultancy Pharmagellan (pharmagellan), an academic researcher and author on life sciences R&D, commercialization, and strategy, and a blogger about biomedical innovation at Forbes. About the Author Frank S. . Seth Robey, PhD, and Andrew Matthews, MD, are former and current associate consultants, respectively, at Pharmagellan. He also maintains an active presence on Twitter (@Frank_S_David)